The suppressive effects of IL-10 and IL-4 (Figure 4A) on TLR-signaling might be relieved by ruxolitinib to account for its ability to activate CLL cells in vivo. This evidence concerns the gene IL10 and B-cell chronic lymphocytic leukemia.